(Q38247122)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201058%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

title

The practical management of refractory schizophrenia--the Maudsley Treatment REview and Assessment Team service approach (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201058%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201058%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Robert McCutcheon

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201058%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Michael Bloomfield

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201058%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Fiona Gaughran

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201058%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Tiago Reis Marques

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201058%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

James H. MacCabe

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201058%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Sudhakar Selvaraj

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201058%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

David Taylor

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201058%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Oliver Howes

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201058%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

R McCutcheon

2

1 reference

1 September 2017

M A P Bloomfield

3

1 reference

1 September 2017

T Reis Marques

5

1 reference

1 September 2017

O D Howes

9

1 reference

1 September 2017

language of work or name

English

0 references

publication date

9 September 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201058%20AND%20SRC:MED&resulttype=core&format=json

Acta Psychiatrica Scandinavica

16 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201058%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

130

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201058%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201058%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

427-438

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25201058%20AND%20SRC:MED&resulttype=core&format=json

Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world

16 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

The social and economic burden of treatment-resistant schizophrenia: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

The cost-effectiveness of clozapine: a controlled, population-based, mirror-image study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Suicidal risk during treatment with clozapine: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

A systematic review of the evidence of clozapine's anti-aggressive effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Substance abuse and schizophrenia: pharmacotherapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Epilepsy, psychosis and clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Myocarditis and cardiomyopathy associated with clozapine use in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Beta-adrenergic antagonists for the treatment of clozapine-induced sinus tachycardia: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Ivabradine, a novel treatment for clozapine-induced sinus tachycardia: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Side effects of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Clozapine-induced hypotension treated with moclobemide and Bovril

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Life-threatening constipation associated with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Clozapine-induced hypersalivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Clozapine-induced sialorrhea: pathophysiology and management strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Combined antipsychotic treatment involving clozapine and aripiprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Atypical antipsychotic dosing: the effect of smoking and caffeine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Cognitive-behavioural therapy for refractory psychotic symptoms of schizophrenia resistant to atypical antipsychotic medication. Randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Influence of patient-related variables on clozapine plasma levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Clozapine-related seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327

The metabolic syndrome and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12327